TY - JOUR
T1 - Therapeutic Strategies To Counteract Antibiotic Resistance in MRSA Biofilm-Associated Infections
AU - Cascioferro, Stella
AU - Carbone, Daniela
AU - Parrino, Barbara
AU - Pecoraro, Camilla
AU - Giovannetti, Elisa
AU - Cirrincione, Girolamo
AU - Diana, Patrizia
N1 - Funding Information: . Elisa Giovannetti is associate Professor of Pharmacology at the VU University Medical Center, Amsterdam, and Principal Investigator at the Cancer Pharmacology Lab (University of Pisa). She is member of the Steering Committee of the Pharmacology and Molecular Mechanisms (PAMM) group of the EORTC, and her studies are funded by grants from Italian Association for Research against Cancer (AIRC), Netherlands Organization for Scientific Research (NWO), Cancer Center Amsterdam (CCA) Foundation, and Dutch Cancer Society (KWF) Publisher Copyright: © 2020 Wiley-VCH GmbH Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1/8
Y1 - 2021/1/8
N2 - Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as one of the leading causes of persistent human infections. This pathogen is widespread and is able to colonize asymptomatically about a third of the population, causing moderate to severe infections. It is currently considered the most common cause of nosocomial infections and one of the main causes of death in hospitalized patients. Due to its high morbidity and mortality rate and its ability to resist most antibiotics on the market, it has been termed a “superbug”. Its ability to form biofilms on biotic and abiotic surfaces seems to be the primarily means of MRSA antibiotic resistance and pervasiveness. Importantly, more than 80 % of bacterial infections are biofilm-mediated. Biofilm formation on indwelling catheters, prosthetic devices and implants is recognized as the cause of serious chronic infections in hospital environments. In this review we discuss the most relevant literature of the last five years concerning the development of synthetic small molecules able to inhibit biofilm formation or to eradicate or disperse pre-formed biofilms in the fight against MRSA diseases. The aim is to provide guidelines for the development of new anti-virulence strategies based on the knowledge so far acquired, and, to identify the main flaws of this research field, which have hindered the generation of new market-approved anti-MRSA drugs that are able to act against biofilm-associated infections.
AB - Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as one of the leading causes of persistent human infections. This pathogen is widespread and is able to colonize asymptomatically about a third of the population, causing moderate to severe infections. It is currently considered the most common cause of nosocomial infections and one of the main causes of death in hospitalized patients. Due to its high morbidity and mortality rate and its ability to resist most antibiotics on the market, it has been termed a “superbug”. Its ability to form biofilms on biotic and abiotic surfaces seems to be the primarily means of MRSA antibiotic resistance and pervasiveness. Importantly, more than 80 % of bacterial infections are biofilm-mediated. Biofilm formation on indwelling catheters, prosthetic devices and implants is recognized as the cause of serious chronic infections in hospital environments. In this review we discuss the most relevant literature of the last five years concerning the development of synthetic small molecules able to inhibit biofilm formation or to eradicate or disperse pre-formed biofilms in the fight against MRSA diseases. The aim is to provide guidelines for the development of new anti-virulence strategies based on the knowledge so far acquired, and, to identify the main flaws of this research field, which have hindered the generation of new market-approved anti-MRSA drugs that are able to act against biofilm-associated infections.
KW - MRSA
KW - antibiotic resistance
KW - antivirulence
KW - biofilms
KW - eradicating agents
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85096055952&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/33090669
U2 - https://doi.org/10.1002/cmdc.202000677
DO - https://doi.org/10.1002/cmdc.202000677
M3 - Review article
C2 - 33090669
SN - 1860-7179
VL - 16
SP - 65
EP - 80
JO - CHEMMEDCHEM
JF - CHEMMEDCHEM
IS - 1
ER -